Top 50 Medical Device VC (Venture Capital) Funds in China in September 2025

Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.

We help founders build enduring companies.

CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.

Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.

BIOCHING CAPITAL is an investment management firm.

Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.

BioTrack Capital is a China-based investment firm.

Zhejiang Haibang Investment Management Co., Ltd. (also referred as "Haibang Capital") is an investment company focusing on venture capital and private equity. It was established in 2011 in Hangzhou. It was founded by Naxin Yao, the CEO of Focused Photonics, Inc (300203), a number of returnee entrepreneurs and experienced investmentprofessionals. In 2011, Haibang Capital launched its first Haibang Fund (formerly called “Haibang Talent Fund”) which was the first venture capital in China helping new returnees to start their own businesses. It is also a fund connect capital and "Thousand Talent Program" in Zhejiang Province. Haibang Capital keeps working on helping enterprises grow rapidly and build leading edge in their industry. In addition to providing capitals, Haibang Capital provides its investee companies with personalized value-added services, helping create both good economic and social benefits.

IDG Capital is an investment firm that funds early- to growth-stage companies in the technology sector. Today they work with private equity and venture capital fund managers, investment advisors, and business entities from around the world. Their limited partners include many internationally reputable investors, including sovereign wealth funds,pension funds, institutional investors, major charities, university endowments, family offices, and business luminaries.IDG Capital brings a powerful combination of global perspective and local experience to investment management. As long-term value investors, they are highly skilled at mobilizing global resources to address local needs, especially for Inbound and outbound opportunities in China and the rest of Asia. Their highly skilled team has an in-depth understanding of the Chinese market and enjoys close relationships with many influential business leaders.

Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.

Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.

Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.

Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.

Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.

Share Capital is a venture capital firm specializing in seed, start-up, early, middle, growth capital, and Pre-IPO investments. it primarily invests in big living, medical healthcare, and internet innovation. In medical healthcare, it seeks to invests in pharmaceuticals, innovative equipment, biotechnology, diagnostic testing equipment andreagents, anti-infectives, drug discovery, medical health service, mobile medical services, and informatization.

Marathon Venture Partners is an international VC fund that focuses on early and growth stage companies in healthcare and Fintech industry.

CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.

Taiyu Investment is an investment firm.

Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.

Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.

SZHTI Group is a company that provides asset management and financing services.

Goldport Capital is a Shenzhen-based asset management company.

Shanlan Capital is a professional fund focused on early and growing health care industry investments with offices in Shanghai and Beijing, focusing on biomedical and medical devices (in vitro diagnostics and gene technology, minimally invasive interventions, implantable devices, minimally invasive High-growth segments such as surgical instrumentsand medical robots, and medical services. It has invested in 15 medical star companies such as Guoke Hengtai, Ricky Surgery, Jingyi Medical, Haipulos, Langhe Medical, etc. The core team of Shanlan Capital is the founder of the medical industry listed company, professional financial and strategic investment. Composition of people, in strategy formulation, talent introduction, technology research and development, market camp..

SND Ventures Group is a venture capital and private equity firm specializing in seed investments.

Fortune Capital, established in April, 2000, is one of the earliest market-oriented venture capital firms in China. For the past 14 years, Fortune Capital focus its investments on leading companies in four key sectors: TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.Fortune Capital is ranked among thehighest performing VC/PE firms in China and selected as "Vice President of Venture Capital Committee of IAC," "Vice President of Shenzhen VC Association," "Vice President of Shenzhen Chamber of International Investment & Funding," etc.In addition to providing capitals, Fortune Capital provides its investee companies with personalized value-added services.

Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics.Founded in 2015, Apricot Capital consists of more than 20 professionals and consultants with experience in thehealthcare industry. Its professional background includes life sciences, medicine, finance and law.

Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.

Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcarefield. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.

HY Capital is a healthcare industry-focused investment firm that engages in early-stage investments, growth-stage investments.

Qiaojing Capital is an investment firm that invests in the medical, consumer & supply chain financial management industries. Qiao Jing Capital's core operation team has experience in senior management positions in well-known asset management companies at home and abroad. The company's operations fully follow the leading models athome and abroad, and pursue strict risk management and efficient incentive mechanisms.

Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.

Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.

ASBV focuses on early and mid-term venture capital investments.

Insight Capital is a venture capital firm focused on early-stage investment.

Taiyu Investment is an investment firm.

Volcanics Venture was founded in May 2016. They identify, invest in, and serve the most promising companies and outstanding entrepreneurs in Internet Innovation, Intelligent Technology and Healthcare industry. Managing Partners Suyang Zhang, Yeshun Dong and Ying Wu have been working closely for years as first-class USD/RMB fund managers.They have more than 60 years of aggregated VC investment and corporate management experience, as well as in-depth understanding of three focused fields. Volcanics Venture brings a powerful combination of global perspective and local experience to investment management, striving to provide sustainable value-added service to their portfolio companies and bring superior return to their limited partners.

By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.

Qingrong Ventures is an Investment firm.

"Founded in 2009, GSR United Capital focuses on equity investment in high-tech industries, focusing on investment and M&A opportunities in advanced manufacturing, next-generation information technology, industrial Internet/digital enterprise services and other fields. GSR United Capital manages both RMB master funds and industrialfunds established with local governments. Since its establishment, GSR United Capital has received strong support from China's top market-oriented mother fund, government-guided fund, wealth management institutions, global 500 enterprises, listed companies and other institutions. Among them, investors with state capital background include Guochuang Yuanhe, Guochuang Kaiyuan, SDIC Unity Capital, China Merchants Venture, Suzhou Fund, Nanchang Industrial Control, Weifang Financial Holding Group, Dongguan Dongcheng, Zhangjiagang Jincheng Investment & Development Co., ltd, etc. Suzhou GSL Venture Capital Management Company, founded in 2011, is a private equity fund manager of the comprehensive fund of GSR United Capital (referred to as "" GSR United Capital ""), and completed the registration of private equity fund manager on May 20, 2014, with the serial number P1002246.""A+ stage is the main stage, the middle and late stage is the auxiliary"" The company focuses on equity investment in high-tech industry, focusing on the strategy of ""A+"" stage, with a capital allocation ratio of 60%. The project in this stage is between ""engineering"" and ""scale commercialization"", which is the ideal range of ""bargaining power"" and can win a high proportion of relative returns. At the same time, 40% of the project will be allocated in the middle and late stages. The middle and late stages refer to enterprises with IPO expectations within 2-3 years, and the investment will be completed within 60 months in the early stage of the fund investment period (exit will start in the third and fourth years), which will be used as the basic plate for anchoring returns.GSR United Capital has invested in more than 100 high-tech start-ups, including Great Wisdom Software (financial information terminal, 601519), eCARBON (high thermal conductivity graphite heat dissipation material, 603133), TZTEK (Precision, 688003), METRON (Diamond wire material, 603133) 300861), GTEP (sludge treatment and recycling, has started the board meeting), Niu (electric two-wheeler, NASDAQ: NIU), LATTICELIGHTING (LED silicon substrate technology and application), Freetech (unmanned driving), Marknum Technology (big data), xMate (light collaborative robot), TAGEIDRIVER (autonomous driving), HUIRUI (high-precision metal 3D printing), DYSO (CNC machine tool parts), NEWLINK GROUP (energy Internet), and many cross-border enterprises Industries such as LianLian (online payment), Xingyun Group (cross-border supply chain), Tec-Do (outbound brand digital marketing, Guangzhou), LAVA (smart guitar, Guangzhou), Shoplazza (outbound SaaS independent site construction tools, Guangzhou), E-ports (Internet for shipping industry), Chenhaiyun (sea-going compliance), Whalehouse.tech (intelligent warehousing), Huoyan (ABM intelligent marketing), Giiso (intelligent writing) and other excellent projects, which have won excess investment returns and social reputation. At present, the withdrawn projects include Great Wisdom Software (Financial information terminal, 601519), which has been fully withdrawn through listing, with return multiple reaching 8.96x, invested by GSR United Capital Phase I; TZTEK (Precision Measurement, 688003.STAR), fully exited through listing with return multiple reaching 2.74x, invested by GSR United Phase II and Botong Jinshi; eCARBON (high thermal conductivity graphite heat dissipation material, 603133), through the listing of all exit, return multiple reached 5x, invested by GSR United Capital Phase I Institute; METRON (Diamond Wire Materials, 300861), which was partially exited through listing with a return multiple of 4.5X and was invested by GSR United Phase III and Botong Jinshi Institute; Lebo Technology (cross-platform screen investment tool), partially exited through equity transfer, with a return multiple of 4.35x, invested by Botong Jinshi. Giiso (Intelligent Collaboration), which was partially withdrawn through equity transfer with a return multiple of 4.35x, was invested by Botong Jinshi.Zerowaste Asia Pte Ltd (ZA) was invested by Hongcheng RMB Fund, a subsidiary of GSR United Capital, in January 2017. It is committed to developing, producing and selling leading additives for heavy metal treatment. Its products have the characteristics of simple process, high efficiency, safety and environmental protection, and low cost. The company's valuation has grown from $58 million at the time of the investment to $142 million.Since February 2020, GSR United Capital has made more than 30 investments in the main fund. For example, it invested in Yuejing Technology (audio and video collaborative production tool) in February 2021, and the current multiple has reached 3.14 times. In September 2020, it invested in ZHICHUBAO.COM (procurement management SaaS platform), and the current multiple has reached 2.82 times. In April 2020, it invested in Starsee Intelligence (AI enabled military defense), and the current multiple has reached 2.81 times. Nahuo Technology Co., Ltd. received a subsequent round of investment from IDG, ZHICHUBAO.COM received a subsequent round of investment from Shunwei Capital, and Boqing Technology received a subsequent round of investment from KeyTone Ventures and Leaguer Capital."

Tsinghua Innovation Ventures is an investment management firm.

Wuxi Capital is a financial investment platform.

China Growth Capital (CGC) is a leading early-stage venture capital firm in China with an extended interest in Silicon Valley. The firm funds seed to Series B in enterprise, technology and marketplace. The typical investment size ranges from $1M to 5M with a hard cap ceiling at $15M per company. Since its founding in 2006, China Growth Capitalhas grown to manage 8 Billion RMB (approximately 1.2 Billion USD) in asset under management across its different RMB and USD funds. Notable portfolio includes SMZDM (300785.SZ), Missfresh (NASDAQ:MF), Wish (NASDAQ:WISH), Tongdun, Tiger Brokers (NASDAQ: TIGR), BeyondHost (now part of Meituan 03690.HK), Ezbuy (NASDAQ:LITB), Cai Cloud (now part of ByteDance), PingCAP, DeePhi (now part of NASDAQ: XLNX), Airlango (now part of HKEX:03690), Nreal, Landspace, WeRide, Plus.ai, Sinovation, Singleron, 4B, ABM Therapeutics and InxMed etc.

Lightspeed China Partners is a leading Chinese venture capital firm focusing on early-stage investments. We are the Chinese partners to Lightspeed Venture Partners. Our expertise is in mobile, Internet, technology-enabled services, and enterprise solution companies. We currently manage three USD funds and one RMB fund.Lightspeed China Partners isalso a young team. We value equality, respect and fairness. Our culture reflects our focus, drive for excellence, and our win-win approach to business.We are dedicated to identifying the next generation of entrepreneurial leaders. To accomplish this , we analyze trends, work with creative teams, and undertake joint efforts to pursue early-stage investments. We are honored to help entrepreneurs because your dream is the greatest thing in the world.

BGI Co-Win is the corporate venture capital arm of BGI and is based in Shenzhen, China.

Tsinghua Innovation Ventures is an investment management firm.

Cenova Capital is one of the earliest healthcare dedicated funds in China founded in 2010 by Dr Jun WU and is one of the earliest investors in private healthcare services and digital health, with helps to facilitate the transformation of healthcare in China from an exclusively state-owned system to a more efficient, market-oriented system. CenovaCapital is healthcare funds dedicated to early and growth-stage investments in the life sciences and healthcare sector in China. Since inception in 2010, Cenova now has five funds under management with investments in over 50 companies in healthcare services, pharmaceuticals, medical devices and digital heath. Cenova's investors are mainly large domestic and international institutional investors including Asian sovereign wealth funds, government institutions, insurance and financial institutions and multinational companies.

Green Pine Capital Partners is a venture capital firm.

Co-Stone Capital is a leading China based private equity firm headquartered in Shenzhen. Founded more than 16 years ago, Co-Stone is one of China's earliest private equity institutions. Co-Stone Capital focuses primarily on China domestic growth stage and Pre-IPO opportunities, basing investment decisions on a deep understanding of the Chineseeconomy and company specific growth patterns. We put heavy emphasis on stable growth in key industries, including TMT, healthcare, consumer products & services and advanced manufacturing. Co-Stone Capital approaches the capital markets with broad vision but detailed focus, maintaining an emphasis on value-adding services. We have invested in over 100 companies, the majority of which were lead investments and have successfully exited from 40 companies through IPO, M&A or reverse mergers. Our exit rates and ROI are far in excess of industry averages. Co-Stone Capital has assets under management in excess of 40 billion RMB, across funds covering private equity, venture capital, PIPE, M&A and fixed income. Co-Stone has a diverse capital base, with LPs ranging across large insurance groups, government guided funds, funds of funds, large corporations, entrepreneurs and high net worth individuals. Co-Stone Capital has received numerous accolades from Forbes, Zero2IPO,ChinaVenture and other industry publications which consistently rank us in the top 10. Co-Stone Capital is headquartered in Shenzhen, with offices in Beijing，Shanghai and Hefei.